Skip to content

Effect of liposomal bupivacaine for preoperative erector spinae plane block on postoperative pain following video-assisted thoracoscopic lung surgery

Effect of liposomal bupivacaine for preoperative erector spinae plane block on postoperative pain following video-assisted thoracoscopic lung surgery: a multicenter, randomized, double-blind, clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074852
Enrollment
Unknown
Registered
2023-08-17
Start date
2023-09-01
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracoscopic lung surgery

Interventions

liposomal bupivacaine group (LB group):preoperative using liposomal bupivacaine for ultrasound-guided erector spinae plane block
bupivacaine HCl group (BUPI group):preoperative using bupivacaine HCl for ultrasound-guided erector spinae plane block

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA class I-III; 2. Aged 18-75 years; 3. Subjects scheduled for elective video-assisted thoracoscopic single or multi-port lung surgery under general anesthesia with bronchial intubation.

Exclusion criteria

Exclusion criteria: 1. Trauma and emergency subjects; 2. New York Heart Function Scale (NYHA) levels 3-4; 3. Heart conduction block (sinus block or atrioventricular block); 4. Unstable coronary artery disease; 5. Gastric ulcer or gastric bleeding; 6. Body mass index (BMI) 37 kg/m2; 7. Diabetes being treated with insulin; 8. Renal dysfunction (serum creatinine values exceed normal thresholds); 9. Liver dysfunction (Alanine aminotransferase or Aspartate aminotransferase is more than twice the normal value); 10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran; 11. Alcohol abuse or heavy dependence on narcotic drugs in the last two months; 12. Uncontrolled anxiety, schizophrenia or other mental illness; 13. Subjects who are pregnant or prepare for pregnancy; 14. Subjects with a history of allergy to local anesthetic drugs or any of the experimental medications.

Design outcomes

Primary

MeasureTime frame
Area under the curve of pain score at rest during 0-72 hours postoperatively (AUC NRS-R 0-72);

Secondary

MeasureTime frame
Total amount of opioid remedial analgesics converted to morphine during 0-72 hours postoperative;Time to first press on the PCIA device as remedial analgesia;Area under the curve of pain scores on activity during 0-72 hours (AUC NRS-A0-72) postoperatively;NRS scores at rest and on activity at different time points during the 72-hour postoperative period;Quality of Recovery 15 (QoR-15) scores at 72 hours after surgery;NRS score on activity on postoperative day 14;NRS scores on activity at postsurgical 3 months;

Countries

China

Contacts

Public ContactFuhai Ji

The First Affiliated Hospital of Soochow University

jifuhai@hotmail.com+86 136 5620 7331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026